Cellestetix, a Turkish biotechnology company specializing in the research, development, and commercialization of plant-based exosome formulations for regenerative beauty care, successfully raised USD 2 million in a recent funding round. This round saw investments from Pragma Capital Partners (PCP), APY Ventures, Arya Ventures, Maxis Ventures, İstCapital, Ahmet Ramiz, and other angel investors.
Founded by genetic engineers Dr. Polen Koçak and Dr. Merve Yıldırım, Cellestetix focuses on cosmetic applications utilizing plant-based exosomes. Through its brand SickScience Labs, the company offers innovative solutions for skin rejuvenation and beauty care, leveraging its advanced plant-based exosome formulations.
Cellestetix made its debut in the US market with SickScience Labs in early 2024, aiming to establish itself as an independent brand. While exosome and product R&D are conducted in Türkiye, the final manufacturing and marketing of products occur at facilities in the US, positioning the company for growth in the competitive US beauty care sector.
Co-founder Dr. Polen Koçak praised the investment, stating, “With our products now available in the US and consistently selling out, SickScience Labs, Inc. is pushing the boundaries of biotechnological cosmetics. Every day, we move closer to our goal of becoming industry leaders with our innovative products and technologies."